Merrimack Pharma (MACK) said to review strategic alternatives - Reuters
- Wall Street rises, buoyed by economic data; Dow sets high
- Twitter (TWTR) 'Takeover Money' Moves On as 'Trump Money' Moves In
- Buy Any Seasonal Market Weakness Ahead of Year End Rally - Oppenheimer (SPY)
- After-Hours Stock Movers 12/05: (TXMD) (COUP) (BOBE) Higher; (SB) (LXRX) (STWD) Lower (more...)
Get daily under-the-radar research with StreetInsider.com's Stealth Growth Insider Get your 2-Wk Free Trial here.
Merrimack Pharma (NASDAQ: MACK) said to review strategic alternatives - Reuters.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- UPDATE: Sanofi (SNY) Said to Explore Counterbid for Actelion Amid Johnson & Johnson (JNJ) Talks - Bloomberg
- Exclusive: U.S. networking company Ixia explores sale - sources
- Burberry rejects multiple takeover offers from Coach: Financial Times